A breakthrough therapy project for the treatment of neurodegeneration to unlock a $60B+ market

**SunRegen is** a Swiss biopharmaceutical pioneer developing the world’s first oral neuro-rescuing therapy with the potential to treat retinal and CNS neurodegenerative diseases. Backed by **Nobel-recognized science**, robust preclinical data, and a **$60B+** market opportunity, SBC003 represents a rare investment opportunity to support a first-in-class therapy with super blockbuster potential.